Targeted Treatment for Differentiated Thyroid Cancer

Lova Sun, MD, discusses genetic alterations in thyroid cancer, including RET and NTRK alterations, and how these can affect treatment options.

Lova Sun, MD, discusses the importance of identifying genetic alterations in thyroid cancer, including RET and NTRK alterations.

Lova Sun, MD, MSCE, discusses targeted therapies for NTRK and RET alterations in thyroid cancers.

Lova Sun, MD, MSCE, discusses resistance mechanisms against targeted agents for the treatment of thyroid cancer.

Lova Sun, MD, MCSE, assistant professor at the Hospital of the University of Pennsylvania, discusses the important of next-generation sequencing for patients with thyroid cancer.

Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses safety data from the phase 3 SELECT trial which evaluated lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses the role of lenvatinib following its approval from the FDA for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses some of the unmet needs that exist in the thyroid cancer space following the FDA approval for lenvatinib for radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, offers advice to oncologists using lenvatinib when treating patients with differentiated thyroid cancer.